Scoping Review Maps How Depression Treatments Fare in Autistic People

Autism spectrum disorder affects nearly 1 in 31 children, and alongside its core social and behavioral features comes a heavy burden of psychiatric comorbidity. Among the most consequential of these co-occurring conditions is major depressive disorder, which researchers estimate affects between 14 and 37 percent of autistic individuals over their lifetimes, a rate that exceeds that of the general population. Yet despite how common depression is in this group, a new scoping review published in Frontiers in Psychiatry concludes that the evidence base for treating it remains strikingly thin, with the strongest signals coming from adapted talk therapies rather than from medication trials designed specifically for autistic people.

The review, conducted by a multi-institution team led by Bharathi Gadad of The University of Texas Rio Grande Valley with collaborators from Harvard Medical School and other institutions, synthesized studies published between 1995 and 2025 that were identified through PubMed and PsycINFO searches along with reference list screening. The authors examined three broad categories of intervention for depressive symptoms in autism: pharmacologic treatments, neuromodulation techniques, and psychosocial approaches. Their goal was not to run a new clinical trial but to map what the existing literature actually shows, and where its most serious gaps lie.

A central theme of the review is that diagnosing depression in autistic people is itself difficult, which complicates every downstream treatment decision. The authors describe diagnostic overshadowing, in which symptoms of depression are mistakenly attributed to autism itself. Symptom overlap adds to the confusion: social withdrawal and fatigue can reflect either condition. Depressive presentations in autism may also be atypical, appearing as irritability or rigidity rather than expressed sadness, and alexithymia, the difficulty identifying and describing one’s own emotions, is common and can obscure internal distress. The review further notes that depression rating scales validated for autistic populations are limited, contributing to underdiagnosis or misdiagnosis.

Against that backdrop, the psychosocial evidence emerged as the most encouraging part of the picture. Autism-adapted cognitive behavioral therapy, mindfulness-based therapy, dialectical behavior therapy-informed approaches, behavioral activation, the PEERS social skills program, exercise, and animal-assisted therapy were all associated with improvements in depressive symptoms. Importantly, these findings come from open-label studies and small randomized trials, not from large, preregistered, well-powered trials. The review highlights that improvements were particularly evident when interventions incorporated visual supports and structural adaptations, suggesting that how a therapy is delivered for autistic participants may matter as much as the therapy itself.

The neuromodulation findings were more tentative. For the more intensive interventions, electroconvulsive therapy and deep brain stimulation, the evidence was largely case-based, meaning individual case reports or small case series rather than controlled studies.

Pharmacologic evidence was the weakest of the three categories. The review notes that recent expert consensus has suggested duloxetine and selected atypical antidepressants, specifically mirtazapine, bupropion, and vortioxetine, may be considered for selected autistic individuals when concerns about the tolerability of selective serotonin reuptake inhibitors arise. The authors are explicit, however, that these recommendations rest primarily on expert consensus and limited indirect evidence rather than on controlled trials conducted in autistic populations.

For clinicians and families, the practical takeaway is one of cautious prioritization rather than a new treatment standard. The reviewed evidence suggests that psychosocial interventions, particularly when adapted with visual and structural supports suited to autistic learners, currently offer the most consistent, if still preliminary, support for reducing depressive symptoms. Medication choices remain guided by consensus and indirect evidence, and device-based treatments remain experimental in this population. What the review makes unmistakably clear is the scale of the unmet need: a condition affecting a substantial fraction of autistic people, with lifetime prevalence estimates reaching as high as 37 percent, is being treated on the basis of evidence that was largely never designed to answer the question.

Subject of Research: Interventions for depressive symptoms in autism spectrum disorder

Article Title: Depression in autism spectrum disorder: a scoping review of pharmacologic, neuromodulation, and psychosocial interventions

Article References: Ghumman, U., Shafee, C., Altarawneh, L., Iorini, M., Kandel, H., Anand, N., Lopez, A., Mendoza, J., Romero, E., Dang, A., Saeed, A., Magisano-Lamraoui, L., Ceranoglu, T. A., Belmares, R., Joshi, G., & Gadad, B. (2026). Depression in autism spectrum disorder: a scoping review of pharmacologic, neuromodulation, and psychosocial interventions. Frontiers in Psychiatry, 17, Article 1906750. https://doi.org/10.3389/fpsyt.2026.1906750

Image Credits: AI Generated

DOI: 10.3389/fpsyt.2026.1906750

Keywords: autism spectrum disorder, major depressive disorder, cognitive behavioral therapy, mindfulness, neuromodulation, pharmacotherapy, scoping review, diagnostic overshadowing, alexithymia, SSRI tolerability, behavioral activation, electroconvulsive therapy